Close Menu

NEW YORK (GenomeWeb) – Swiss contract research firm Intomics said today that it has inked an agreement to collaborate with Actelion Pharmaceuticals on research into neurodegenerative diseases.

Intomics said that the partners will apply a systems biology approach to gain a better understanding of the pathological processes underlying human neurodegenerative diseases at the molecular level with a long-term goal of facilitating better treatments for patients with such diseases.

Terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The first reported coronavirus cases in Europe and the US might not be related to the subsequent outbreaks in those areas, according to the New York Times.

According to NPR, there's a growing shortage of machines to run SARS-CoV-2 tests.

The Wall Street Journal and Kaiser Health News report that antibody testing for SARS-CoV-2 has led to further confusion.

In Nature this week: the largest known collection of human genetic variants, and more.

Jul
09
Sponsored by
Illumina

In this webinar, Dr. Charlie Johnson, founder of the Texas A&M AgriLife Genomics and Bioinformatics Service, will share how his team is utilizing Illumina’s DRAGEN informatics platform in its high-throughput agrigenomics research program.